{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:51:32Z","timestamp":1790715092732,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,7,10]],"date-time":"2009-07-10T00:00:00Z","timestamp":1247184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1472-6963-9-115","type":"journal-article","created":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T02:15:10Z","timestamp":1248747310000},"source":"Crossref","is-referenced-by-count":129,"title":["Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers"],"prefix":"10.1186","volume":"9","author":[{"given":"Astrid","family":"Langer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,10]]},"reference":[{"issue":"2","key":"986_CR1","first-page":"125","volume":"26","author":"B Allenet","year":"2000","unstructured":"Allenet B, Paree F, Lebrun T, Carr L, Posnett J, Martini J, Yvon C: Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context. Diabetes Metab. 2000, 26 (2): 125-132.","journal-title":"Diabetes Metab"},{"key":"986_CR2","volume-title":"Technology Report","author":"C Ho","year":"2005","unstructured":"Ho C, Tran K, Hux M, Sibbald G, Campbell K: Artificial skin grafts in chronic wound care: A meta-analysis of clinical efficacy and a review of cost-effectiveness. Technology Report. 2005, Ottawa: CCOHTA, 52."},{"issue":"2","key":"986_CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers S, Goossens M, Vet H, van Tulder M, Ament A: Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care. 2005, 21 (2): 240-245.","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"36","key":"986_CR4","doi-asserted-by":"publisher","first-page":"iii-iv, ix-xi","DOI":"10.3310\/hta8360","volume":"8","author":"Z Philips","year":"2004","unstructured":"Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacott N, Glanville J: A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004, 8 (36): iii-iv, ix-xi-1-158.","journal-title":"Health Technol Assess"},{"issue":"Suppl 1","key":"986_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1524-4733.2000.36027.x","volume":"3","author":"U Persson","year":"2000","unstructured":"Persson U, Willis M, Odegaard K, Apelqvist J: The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health. 2000, 3 (Suppl 1): 39-46. 10.1046\/j.1524-4733.2000.36027.x.","journal-title":"Value Health"},{"issue":"4","key":"986_CR6","first-page":"243","volume":"3","author":"O Ghatnekar","year":"2000","unstructured":"Ghatnekar O, Persson U, Willis M, Wright T, \u00d6degaard K: The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel. Journal of Drug Assessment. 2000, 3 (4): 243-251.","journal-title":"Journal of Drug Assessment"},{"issue":"7","key":"986_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00019053-200119070-00005","volume":"19","author":"O Ghatnekar","year":"2001","unstructured":"Ghatnekar O, Persson U, Willis M, \u00d6degaard K: Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics. 2001, 19 (7): 767-778. 10.2165\/00019053-200119070-00005.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"986_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1524-475X.1999.00335.x","volume":"7","author":"JM Smiell","year":"1999","unstructured":"Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH: Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 1999, 7 (5): 335-346. 10.1046\/j.1524-475X.1999.00335.x.","journal-title":"Wound Repair Regen"},{"issue":"4","key":"986_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1046\/j.1524-4725.2001.00280.x","volume":"27","author":"J Kantor","year":"2001","unstructured":"Kantor J, Margolis DJ: Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg. 2001, 27 (4): 347-351. 10.1046\/j.1524-4725.2001.00280.x.","journal-title":"Dermatol Surg"},{"issue":"2A Suppl","key":"986_CR10","doi-asserted-by":"publisher","first-page":"74S","DOI":"10.1016\/S0002-9610(98)00185-8","volume":"176","author":"TJ Wieman","year":"1998","unstructured":"Wieman TJ: Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg. 1998, 176 (2A Suppl): 74S-79S. 10.1016\/S0002-9610(98)00185-8.","journal-title":"Am J Surg"},{"issue":"11","key":"986_CR11","first-page":"76","volume":"49","author":"RG Sibbald","year":"2003","unstructured":"Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N: Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage. 2003, 49 (11): 76-84.","journal-title":"Ostomy Wound Manage"},{"issue":"5","key":"986_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2337\/diacare.21.5.822","volume":"21","author":"TJ Wieman","year":"1998","unstructured":"Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998, 21 (5): 822-827. 10.2337\/diacare.21.5.822.","journal-title":"Diabetes Care"},{"key":"986_CR13","first-page":"xiii","volume-title":"The Treatment of Venous Leg Ulcers and Optimal Use of ApligrafTM","author":"A\u00c9TMIS","year":"2001","unstructured":"A\u00c9TMIS: The Treatment of Venous Leg Ulcers and Optimal Use of ApligrafTM. 2001, Montreal: A\u00c9TMIS, xiii-132."},{"issue":"3","key":"986_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/archderm.134.3.293","volume":"134","author":"V Falanga","year":"1998","unstructured":"Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, Jensen J, Sabolinski M, Hardin-Young J: Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998, 134 (3): 293-300. 10.1001\/archderm.134.3.293.","journal-title":"Arch Dermatol"},{"issue":"4","key":"986_CR15","first-page":"142","volume":"14","author":"J Steinberg","year":"2002","unstructured":"Steinberg J, Beusterien K, Plante K, Nordin J, Chaikoff E, Arcona S, Kim J, Belletti DA: A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers. Wounds-a Compendium of Clinical Research and Practice. 2002, 14 (4): 142-149.","journal-title":"Wounds-a Compendium of Clinical Research and Practice"},{"issue":"2","key":"986_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/diacare.24.2.290","volume":"24","author":"A Veves","year":"2001","unstructured":"Veves A, Falanga V, Armstrong DG, Sabolinski ML: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001, 24 (2): 290-295. 10.2337\/diacare.24.2.290.","journal-title":"Diabetes Care"},{"key":"986_CR17","first-page":"49","volume":"10","author":"L Segal","year":"2002","unstructured":"Segal L, John S: The use of Dermagraft\u00ae in neuropathic foot ulcers in people with diabetes: an economic analysis for Australia. PRIMARY INTENTION. 2002, 10: 49-60.","journal-title":"PRIMARY INTENTION"},{"issue":"11","key":"986_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1525-1594.1997.tb00476.x","volume":"21","author":"G Naughton","year":"1997","unstructured":"Naughton G, Mansbridge J, Gentzkow G: A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs. 1997, 21 (11): 1203-1210.","journal-title":"Artif Organs"},{"key":"986_CR19","doi-asserted-by":"crossref","unstructured":"Harding K, Cutting K, Price P: The cost-effectiveness of wound management protocols of care. Br J Nurs. 2000, 9 (19 Suppl).","DOI":"10.12968\/bjon.2000.9.Sup3.12483"},{"issue":"11","key":"986_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/00115677-200109110-00005","volume":"9","author":"MD Kerstein","year":"2001","unstructured":"Kerstein MD, Gemmen E, van Rijswijk L, Lyder CH, Phillips T, Xakellis G, Golden K, Harrington C: Cost and cost effectiveness of venous and pressure ulcer protocols of care. Dis Manage Health Outcomes. 2001, 9 (11): 651-663. 10.2165\/00115677-200109110-00005.","journal-title":"Dis Manage Health Outcomes"},{"issue":"6","key":"986_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.12968\/jowc.2002.11.6.26408","volume":"11","author":"S Meaume","year":"2002","unstructured":"Meaume S, Gemmen E: Cost-effectiveness of wound management in France: pressure ulcers and venous leg ulcers. J Wound Care. 2002, 11 (6): 219-224.","journal-title":"J Wound Care"},{"key":"986_CR22","volume-title":"Diabetes 1999., (Supplement): Abstract no. 829","author":"D Amato","year":"1999","unstructured":"Amato D, Persson U, Lantin M, Basso K, Martens L: The cost of illness in patients with diabetic foot ulcers . Diabetes 1999., (Supplement): Abstract no. 829. 1999, ., (Supplement): Abstract no. 829"},{"issue":"5","key":"986_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2796.1994.tb01104.x","volume":"235","author":"J Apelqvist","year":"1994","unstructured":"Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J: Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation. J Intern Med. 1994, 235 (5): 463-471.","journal-title":"J Intern Med"},{"issue":"7","key":"986_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/107110079501600702","volume":"16","author":"J Apelqvist","year":"1995","unstructured":"Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson U: Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int. 1995, 16 (7): 388-394.","journal-title":"Foot Ankle Int"},{"issue":"2","key":"986_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1464-5491.1995.tb00442.x","volume":"12","author":"J Apelqvist","year":"1995","unstructured":"Apelqvist J, Ragnarson-Tennvall G, Larsson J: Topical treatment of diabetic foot ulcers: an economic analysis of treatment alternatives and strategies. Diabet Med. 1995, 12 (2): 123-128.","journal-title":"Diabet Med"},{"issue":"1","key":"986_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2165\/00019053-199712010-00005","volume":"12","author":"G Ragnarson-Tennvall","year":"1997","unstructured":"Ragnarson-Tennvall G, Apelqvist J: Cost-effective management of diabetic foot ulcers. A review. Pharmacoeconomics. 1997, 12 (1): 42-53. 10.2165\/00019053-199712010-00005.","journal-title":"Pharmacoeconomics"},{"issue":"16","key":"986_CR27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2165\/00019053-200321160-00003","volume":"21","author":"WK Redekop","year":"2003","unstructured":"Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z: The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003, 21 (16): 1171-1183. 10.2165\/00019053-200321160-00003.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"986_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1524-475x.2000.00251.x","volume":"8","author":"WH Schonfeld","year":"2000","unstructured":"Schonfeld WH, Villa KF, Fastenau JM, Mazonson PD, Falanga V: An economic assessment of Apligraf (Graftskin) for the treatment of hard-to-heal venous leg ulcers. Wound Repair Regen. 2000, 8 (4): 251-257. 10.1046\/j.1524-475x.2000.00251.x.","journal-title":"Wound Repair Regen"},{"issue":"8","key":"986_CR29","first-page":"36","volume":"47","author":"RG Sibbald","year":"2001","unstructured":"Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P: Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 2001, 47 (8): 36-46.","journal-title":"Ostomy Wound Manage"},{"issue":"1","key":"986_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1742-481X.2007.00342.x","volume":"5","author":"K Furtado","year":"2008","unstructured":"Furtado K, Pina E, Moffatt CJ, Franks PJ: Leg ulceration in Portugal: quality of life. Int Wound J. 2008, 5 (1): 34-39.","journal-title":"Int Wound J"},{"issue":"1","key":"986_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0965-206X(01)80013-9","volume":"11","author":"S Loftus","year":"2001","unstructured":"Loftus S: A longitudinal, quality of life study comparing four layer bandaging and superficial venous surgery for the treatment of venous leg ulcers. J Tissue Viability. 2001, 11 (1): 14-19.","journal-title":"J Tissue Viability"},{"issue":"5","key":"986_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8727(00)00133-1","volume":"14","author":"G Ragnarson Tennvall","year":"2000","unstructured":"Ragnarson Tennvall G, Apelqvist J: Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complications. 2000, 14 (5): 235-241. 10.1016\/S1056-8727(00)00133-1.","journal-title":"J Diabetes Complications"},{"issue":"4","key":"986_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1023\/A:1008992006845","volume":"8","author":"SJ Walters","year":"1999","unstructured":"Walters SJ, Morrell CJ, Dixon S: Measuring health-related quality of life in patients with venous leg ulcers. Qual Life Res. 1999, 8 (4): 327-336. 10.1023\/A:1008992006845.","journal-title":"Qual Life Res"},{"issue":"2","key":"986_CR34","first-page":"76","volume":"13","author":"SD Mathias","year":"2000","unstructured":"Mathias SD, Prebil LA, Boyko WL, Fastenau J: Health-related quality of life in venous leg ulcer patients successfully treated with Apligraf: a pilot study. Adv Skin Wound Care. 2000, 13 (2): 76-78.","journal-title":"Adv Skin Wound Care"},{"issue":"13","key":"986_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","volume":"22","author":"R Welte","year":"2004","unstructured":"Welte R, Feenstra T, Jager H, Leidl R: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004, 22 (13): 857-876. 10.2165\/00019053-200422130-00004.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"986_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005650-200301000-00001","volume":"41","author":"SC Stearns","year":"2003","unstructured":"Stearns SC, Drummond M: Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts?. Med Care. 2003, 41 (1): 1-3. 10.1097\/00005650-200301000-00001.","journal-title":"Med Care"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-9-115\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-9-115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-9-115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-9-115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T14:37:51Z","timestamp":1558449471000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-9-115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-9-115","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,10]]},"article-number":"115"}}